findmyKOL
Clinical trialNCT04156685CompletedPhase 1Interventional

Pharmacokinetics, Safety and Tolerability of CKD-387 10/500mg BE Phase1

SponsorChong Kun Dang PharmaceuticalEnrollment58Type2 Diabetes Mellitus
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Ji-Young Park, M.D, Ph.D

    Korea University Anam Hospital / Seoul, Seongbuk-Gu, South Korea

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

South Korea
  • Korea University Anam Hospital

    Seoul, Seongbuk-Gu, South Korea

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
6 Aug 2019
Primary completion
30 Aug 2019
Completion
2 Oct 2019
Last update posted
7 Nov 2019
Registered enrollment
58
Registry id
NCT04156685

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.